ArticleClinical kidney journal2022
Association of anti-neutrophil cytoplasmic antibody-associated vasculitis and cardiovascular events: a population-based cohort study.
Article in Clinical kidney journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Pooled it
- Cardiovascular and thromboembolic risk in ANCA-associated vasculitis: a nationwide matched cohort study by disease, sex and familial risk.Rheumatology (Oxford, England) · 2026Article
- Review
- Hydralazine Use and Risk of Vasculitis.JAMA network open · 2026Article
- Impact of ANCA specificity on risk of cardiovascular events and death in ANCA-associated vasculitis.RMD open · 2026Article
- ANCA-associated vasculitis is associated with an increased risk of cardiac and vascular morbidity: results of a large-scale propensity-matched global retrospective cohort study.Frontiers in immunology · 2026Article
- Myocardial infarction in ANCA-associated vasculitis: a population-based cohort study.RMD open · 2025Article
- Relapses and serious adverse events during rituximab maintenance therapy in ANCA-associated vasculitis: a multicentre retrospective study.Rheumatology (Oxford, England) · 2025Article
- Remnant Cholesterol Levels at Diagnosis May Predict Acute Coronary Syndrome Occurrence During Follow-Up in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Journal of clinical medicine · 2025Article
- Age-Related Variations in the Clinical Presentation and Treatment Outcomes of New-Onset GPA: A Longitudinal Study.Journal of clinical medicine · 2025Article
- Minimally Invasive Surgical Approach in Granulomatosis with Polyangiitis Complicated with Intramural Descending Aorta Hematoma Followed by Aortic Wall Rupture.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Integrated bioinformatic analysis of the shared molecular mechanisms between ANCA-associated vasculitis and atherosclerosis.Arthritis research & therapy · 2024Article
- Assessment of cardiovascular risk in patients with ANCA-associated vasculitis: A systematic review and meta-analysis.International journal of cardiology. Cardiovascular risk and prevention · 2024Review
- Rare Clinical Manifestation of Vasculitis.Diagnostics (Basel, Switzerland) · 2024Article
- Diagnostic and prognostic role of serum interleukin-6 and carotid ultrasonography to detect subclinical atherosclerosis in patients with RA and ANCA-associated vasculitis.Rheumatology international · 2024Article
- Antineutrophil Cytoplasmic Antibody Vasculitis after Coronary Artery Bypass Grafting.Case reports in surgery · 2024Article
- Cardiovascular Disease in Anti-neutrophil Cytoplasm Antibody-Associated Vasculitis.Current rheumatology reports · 2024Review
- Spleen tyrosine kinase (SYK) signals are implicated in cardio-cerebrovascular diseases.Heliyon · 2023Review
- Cardiovascular risk assessment in lupus nephritis and ANCA-associated vasculitis in real-world nephrology practice.Clinical kidney journal · 2022Article
Corrections and comments
- Comment on
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is implicated in elevating the risk for cardiovascular (CV) disease; whether the elevated risk applies to all types of CV diseases or specific types is unclear. This study examined the association of AAV and adverse CV outcomes compared with the non-AAV population. Methods: We conducted a population-based, retrospective cohort study of adults (mean age 61 years, 51% female) with a new diagnosis of AAV in Ontario, Canada from 2007 to 2017. Weighted models were used to examine the association of AAV ( Results: Over a mean follow-up of 3.8 years, AAV (compared with non-AAV) was associated with a higher risk of stroke: cumulative incidence 7.0% versus 5.2%, sub-distribution hazard ratio (sHR) 1.49 [(95% confidence interval (95% CI) 1.10-2.02]; AF: cumulative incidence 16.4% versus 11.5%, sHR 1.51, 95% CI 1.30-1.75; and CHF: cumulative incidence 20.8% versus 13.3%, sHR 1.41, 95% CI 1.22-1.62; but not for MACE, MI or CV death. The risks for all CV events, except CV death, were significantly elevated in the early period after AAV diagnosis, in particular AF (365-day sHR 2.06, 95% CI 1.71-2.48; 90-day sHR 3.33, 95% CI 2.66-4.18) and CHF (365-day sHR 1.75, 95% CI 1.48-2.07; 90-day sHR 2.65, 95% CI 2.15-3.26). Conclusion: AAV is associated with a high risk of certain types of CV events, particularly in the early period following diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.